Page 17 - Accelerated Approval Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Posted on 532 Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Tricida, Inc. (NasdaqGS: TCDA). On July 15, 2020, the Company disclosed that it received a notification from the U.S. Food and Drug Administration (FDA) regarding its ongoing review of the Company’s New Drug Application (NDA) for its drug candidate, veverimer (TRC101) wherein “the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.” Then, on October 29, 2020, the Company announced an update on its End-of-Review Type A meeting with the FDA regarding the veverimer NDA, and “now believes the FDA will also require evidence of veverimer’s effect on CKD progression from a near-term interim analysis of the VALOR-CKD trial for approval under the Acc

New yorkUnited statesLewis kahnCharlesc foti jrCompany new drug applicationTricida incApproval programDrug administrationKahn swick fotiFormer attorney generalKahn swickNew drug applicationEnd of review typeAccelerated approval programClass periodPartner lewis kahn